Several PSMA-based vaccines had been developed and it has been observed in a phase II trial utilizing MHC Class I-restricted peptides that PSMA can induce immune responses in patients with advanced carcinoma of prostate and alleviate the disease [29-31]. The gene discussed is FOLH1; the disease is prostate carcinoma.